<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002025</url>
  </required_header>
  <id_info>
    <org_study_id>029D</org_study_id>
    <secondary_id>ICM 1691</secondary_id>
    <nct_id>NCT00002025</nct_id>
  </id_info>
  <brief_title>Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient</brief_title>
  <official_title>Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To make intravenous (IV) ganciclovir available to immunocompromised patients with&#xD;
      life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of&#xD;
      the disease are too severe to allow admission to a controlled clinical study of ganciclovir&#xD;
      therapy. To determine the safety and tolerance of 2 - 3 weeks induction course of ganciclovir&#xD;
      IV followed by a maintenance course of ganciclovir IV for an indefinite duration. To tabulate&#xD;
      the patient's clinical response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Cytomegalovirus (CMV) disease who meet the criteria for a treatment IND protocol, or&#xD;
             other clinical studies, including controlled clinical studies of anticytomegalovirus&#xD;
             therapy in peripheral CMV retinitis in patients with AIDS.&#xD;
&#xD;
          -  Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome&#xD;
             (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered&#xD;
             immediately life-threatening.&#xD;
&#xD;
          -  Transplant patients in whom trial reduction of immunosuppressive drug treatment is&#xD;
             feasible.&#xD;
&#xD;
          -  Children with congenital or neonatal CMV where there is not a documented primary or&#xD;
             acquired immunodeficiency.&#xD;
&#xD;
          -  Hypersensitivity to acyclovir or ganciclovir.&#xD;
&#xD;
          -  Receiving antimetabolite treatment that cannot be discontinued.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antimetabolites.&#xD;
&#xD;
          -  Alkylating agents.&#xD;
&#xD;
          -  Nucleoside analogs (topical ophthalmics are permitted).&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Cytokines.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Cytomegalovirus (CMV) infection who meet the criteria for a treatment IND protocol, or&#xD;
             other clinical studies, including controlled clinical studies of anticytomegalovirus&#xD;
             therapy in peripheral CMV retinitis in patients with AIDS.&#xD;
&#xD;
          -  Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome&#xD;
             (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered&#xD;
             immediately life-threatening.&#xD;
&#xD;
          -  Transplant patients in whom trial reduction of immunosuppressive drug treatment is&#xD;
             feasible.&#xD;
&#xD;
          -  Children with congenital or neonatal CMV where there is not a documented primary or&#xD;
             acquired immunodeficiency.&#xD;
&#xD;
          -  Hypersensitivity to acyclovir or ganciclovir.&#xD;
&#xD;
          -  Receiving antimetabolite treatment that cannot be discontinued.&#xD;
&#xD;
        Patients must qualify as follows:&#xD;
&#xD;
          -  Previously enrolled in compassionate use study (ICM 1257/1257A) or have terminated&#xD;
             from another Syntex ganciclovir study.&#xD;
&#xD;
          -  Diagnosis of AIDS and life-threatening Cytomegalovirus (CMV) infection.&#xD;
&#xD;
          -  Diagnosis of other immunodeficiencies other than AIDS, with life-threatening or&#xD;
             sight-threatening CMV disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Roche Global Development - Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Retinitis</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Immune Tolerance</keyword>
  <keyword>Injections, Intravenous</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

